Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS

Gynecological Endocrinology

Volumn 30, Issue 3, 2014, Pages 205-208

  Pizzo, Alfonsa ^a   Laganà, Antonio Simone ^a   Barbaro, Luisa ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Family Counseling Center   (Italy)

Author keywords

d Chiro inositol; Metabolic factors; Myo inositol; Ovarian function; Polycystic ovary syndrome

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ANDROSTENEDIONE; DEXTRO INOSITOL; FOLIC ACID; FOLLITROPIN; GLUCOSE; IMMUNOREACTIVE INSULIN; INOSITOL; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CREMONCINI SCORE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOCRINE FUNCTION; FEMALE; FERRIMAN GALLWEY SCORE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; METABOLIC PARAMETERS; METABOLISM; METRORRHAGIA; OLIGOMENORRHEA; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECONDARY AMENORRHEA; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; YOUNG ADULT;

ADOLESCENT; ADULT; AMENORRHEA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; HYPERTENSION; INOSITOL; INSULIN RESISTANCE; ITALY; LUTEINIZING HORMONE; MENSTRUATION DISTURBANCES; METRORRHAGIA; OLIGOMENORRHEA; OVARY; POLYCYSTIC OVARY SYNDROME; STEREOISOMERISM; YOUNG ADULT;

EID: 84894554207     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.860120     Document Type: Article

References (20)

1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9.
2. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-97.
3. Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Invest 2012;35: 317-21.
4. Gonza'lez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336-40.
5. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989;31:87-120.
6. James RG, Krakower GR, Kissebah AH. Influence of androgenicity on adipocytes and precursor cells in female rats. Obes Res 1996;4: 463-70.
7. Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin - two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch 2008;48:9-15.
8. Norman RJ, Clark AM. Lifestyle factors in the aetioloy and management of polycystic ovary syndrome. In: Kovacs GT, ed, Polycystic ovary syndrome. 1st ed. Cambridge: Cambridge University Press; 2000, pp. 98-116.
9. Ku̧sçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand 2009;88:612-7.
10. Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003;80:252-4.
11. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
12. Landay M, Huang A, Azziz R. Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril 2009;92:643-7.
13. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390-7.
14. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-44.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
16. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13:105-10.
17. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myoinositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009; 147:120-3.
18. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16:575-81.
19. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-20.
20. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of D-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417-23.